FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017322529> ?p ?o ?g. }

• W2017322529 endingPage "78" @default.
• W2017322529 startingPage "78" @default.
• W2017322529 abstract "ADV is a serious cause of morbidity and mortality in patients undergoing alloSCT. ADV infection rates are 4-6% in adults and as high as 47% in children following alloSCT (Hoffman et al BBMT 2001). The reported mortality rate for disseminated ADV ranges from 8-54 % with higher rates reported in patients with ADV pneumonia (73%) and disseminated disease (61%) (Ljungman, Eur J Clin Microbiol & Infect Dis, 2004). We sought to determine the incidence, demographics, site of disease, treatment course, and outcome of ADV infection in children and adolescents following alloSCT from 1/1/2000-12/31/04. Eighty three children and adolescents underwent 91 alloSCT. Median age 6.5 (0.5 – 21.75) years, sex: M/F (52/39). AlloSCT donors included: Matched Family Donor (MFD), Bone Marrow (BM)/Peripheral Blood (PB) – 34 (37.4%), Unrelated Cord Blood(UCB) – 51 (56%), Related Cord Blood(RCB) - 3 (3.3%), Matched Unrelated Donor(MUD) – 3 (3.3%). Conditioning: 36 (40%) ablative conditioning, 55 (60%) reduced intensity conditioning. The majority (>90%) received Mycophenolate Mofetil/Tacrolimus GVHD prophylaxis (Osunkwo/Cairo et al, BBMT 2004). Recipients at risk for CMV received Foscarnet/Ganciclovir prophylaxis (Shereck/Cairo et al PBC 2006). ADV swabs and tissue biopsies samples cultured in remel microtest viral media. Ten (11%) systemic and/or invasive ADV infections were identified. Underlying diagnosis: 5 malignant (1ALL, 1 AML, 1 NHL, 2 NBL), 5 non-malignant (1WAS, 4 SAA). Donor source: 4 UCB, 1 MUD, 2 MFDPB, 1 MFDBM, 2 MFDBM + PB. Sites of ADV + culture: Gastroenteritis (GE) – 4, GE/Pneumonitis – 3, GE/Nasopharyngeal – 2, Cystits – 1. Treatment (Tx): cidofovir (CDV) (1mg/kg TIW) [n=8], observation [n=1], ADV found on post-mortem culture [n=1]. Outcome: 8 expired (6 non-ADV infection, 1 GVHD, 1 CNS hemorrhage); 2 survivors (1 post tx with no evidence of ADV, 1 ADV + no tx.) There were no ADV related deaths for 0% mortality. Adenovirus infection is an important contributor to post alloSCT morbidity and mortality. In patients transplanted at our center from 1/2000 –12/31/04 there was an 11 % incidence of adenovirus infection. Tx with CDV improves the outcome of patients with ADV infection in the post-transplant period. More rapid diagnosis with PCR-based technology will allow earlier diagnosis of systemic disease in alloSCT recipients resulting in prompt therapeutic intervention which may lead to improved outcomes. ADV is a serious cause of morbidity and mortality in patients undergoing alloSCT. ADV infection rates are 4-6% in adults and as high as 47% in children following alloSCT (Hoffman et al BBMT 2001). The reported mortality rate for disseminated ADV ranges from 8-54 % with higher rates reported in patients with ADV pneumonia (73%) and disseminated disease (61%) (Ljungman, Eur J Clin Microbiol & Infect Dis, 2004). We sought to determine the incidence, demographics, site of disease, treatment course, and outcome of ADV infection in children and adolescents following alloSCT from 1/1/2000-12/31/04. Eighty three children and adolescents underwent 91 alloSCT. Median age 6.5 (0.5 – 21.75) years, sex: M/F (52/39). AlloSCT donors included: Matched Family Donor (MFD), Bone Marrow (BM)/Peripheral Blood (PB) – 34 (37.4%), Unrelated Cord Blood(UCB) – 51 (56%), Related Cord Blood(RCB) - 3 (3.3%), Matched Unrelated Donor(MUD) – 3 (3.3%). Conditioning: 36 (40%) ablative conditioning, 55 (60%) reduced intensity conditioning. The majority (>90%) received Mycophenolate Mofetil/Tacrolimus GVHD prophylaxis (Osunkwo/Cairo et al, BBMT 2004). Recipients at risk for CMV received Foscarnet/Ganciclovir prophylaxis (Shereck/Cairo et al PBC 2006). ADV swabs and tissue biopsies samples cultured in remel microtest viral media. Ten (11%) systemic and/or invasive ADV infections were identified. Underlying diagnosis: 5 malignant (1ALL, 1 AML, 1 NHL, 2 NBL), 5 non-malignant (1WAS, 4 SAA). Donor source: 4 UCB, 1 MUD, 2 MFDPB, 1 MFDBM, 2 MFDBM + PB. Sites of ADV + culture: Gastroenteritis (GE) – 4, GE/Pneumonitis – 3, GE/Nasopharyngeal – 2, Cystits – 1. Treatment (Tx): cidofovir (CDV) (1mg/kg TIW) [n=8], observation [n=1], ADV found on post-mortem culture [n=1]. Outcome: 8 expired (6 non-ADV infection, 1 GVHD, 1 CNS hemorrhage); 2 survivors (1 post tx with no evidence of ADV, 1 ADV + no tx.) There were no ADV related deaths for 0% mortality. Adenovirus infection is an important contributor to post alloSCT morbidity and mortality. In patients transplanted at our center from 1/2000 –12/31/04 there was an 11 % incidence of adenovirus infection. Tx with CDV improves the outcome of patients with ADV infection in the post-transplant period. More rapid diagnosis with PCR-based technology will allow earlier diagnosis of systemic disease in alloSCT recipients resulting in prompt therapeutic intervention which may lead to improved outcomes." @default.
• W2017322529 created "2016-06-24" @default.
• W2017322529 creator A5001697191 @default.
• W2017322529 creator A5019068922 @default.
• W2017322529 creator A5023801072 @default.
• W2017322529 creator A5033104475 @default.
• W2017322529 creator A5034977545 @default.
• W2017322529 creator A5041488382 @default.
• W2017322529 creator A5043335221 @default.
• W2017322529 creator A5048733835 @default.
• W2017322529 creator A5049279048 @default.
• W2017322529 creator A5051652369 @default.
• W2017322529 creator A5066133666 @default.
• W2017322529 creator A5066384049 @default.
• W2017322529 creator A5066731966 @default.
• W2017322529 creator A5077627873 @default.
• W2017322529 creator A5090974164 @default.
• W2017322529 date "2007-02-01" @default.
• W2017322529 modified "2023-09-24" @default.
• W2017322529 title "212: Adenovirus (ADV) infections following allogeneic stem cell transplant (alloSCT) in children and adolescent recepients" @default.
• W2017322529 doi "https://doi.org/10.1016/j.bbmt.2006.12.216" @default.
• W2017322529 hasPublicationYear "2007" @default.
• W2017322529 type Work @default.
• W2017322529 sameAs 2017322529 @default.
• W2017322529 citedByCount "0" @default.
• W2017322529 crossrefType "journal-article" @default.
• W2017322529 hasAuthorship W2017322529A5001697191 @default.
• W2017322529 hasAuthorship W2017322529A5019068922 @default.
• W2017322529 hasAuthorship W2017322529A5023801072 @default.
• W2017322529 hasAuthorship W2017322529A5033104475 @default.
• W2017322529 hasAuthorship W2017322529A5034977545 @default.
• W2017322529 hasAuthorship W2017322529A5041488382 @default.
• W2017322529 hasAuthorship W2017322529A5043335221 @default.
• W2017322529 hasAuthorship W2017322529A5048733835 @default.
• W2017322529 hasAuthorship W2017322529A5049279048 @default.
• W2017322529 hasAuthorship W2017322529A5051652369 @default.
• W2017322529 hasAuthorship W2017322529A5066133666 @default.
• W2017322529 hasAuthorship W2017322529A5066384049 @default.
• W2017322529 hasAuthorship W2017322529A5066731966 @default.
• W2017322529 hasAuthorship W2017322529A5077627873 @default.
• W2017322529 hasAuthorship W2017322529A5090974164 @default.
• W2017322529 hasBestOaLocation W20173225291 @default.
• W2017322529 hasConcept C120665830 @default.
• W2017322529 hasConcept C121332964 @default.
• W2017322529 hasConcept C126322002 @default.
• W2017322529 hasConcept C141071460 @default.
• W2017322529 hasConcept C2779972918 @default.
• W2017322529 hasConcept C2780914630 @default.
• W2017322529 hasConcept C2909675724 @default.
• W2017322529 hasConcept C2911091166 @default.
• W2017322529 hasConcept C61511704 @default.
• W2017322529 hasConcept C71924100 @default.
• W2017322529 hasConcept C90924648 @default.
• W2017322529 hasConceptScore W2017322529C120665830 @default.
• W2017322529 hasConceptScore W2017322529C121332964 @default.
• W2017322529 hasConceptScore W2017322529C126322002 @default.
• W2017322529 hasConceptScore W2017322529C141071460 @default.
• W2017322529 hasConceptScore W2017322529C2779972918 @default.
• W2017322529 hasConceptScore W2017322529C2780914630 @default.
• W2017322529 hasConceptScore W2017322529C2909675724 @default.
• W2017322529 hasConceptScore W2017322529C2911091166 @default.
• W2017322529 hasConceptScore W2017322529C61511704 @default.
• W2017322529 hasConceptScore W2017322529C71924100 @default.
• W2017322529 hasConceptScore W2017322529C90924648 @default.
• W2017322529 hasIssue "2" @default.
• W2017322529 hasLocation W20173225291 @default.
• W2017322529 hasOpenAccess W2017322529 @default.
• W2017322529 hasPrimaryLocation W20173225291 @default.
• W2017322529 hasRelatedWork W1204386133 @default.
• W2017322529 hasRelatedWork W2009118697 @default.
• W2017322529 hasRelatedWork W2016455547 @default.
• W2017322529 hasRelatedWork W2077425645 @default.
• W2017322529 hasRelatedWork W2144565646 @default.
• W2017322529 hasRelatedWork W2560118270 @default.
• W2017322529 hasRelatedWork W2560208761 @default.
• W2017322529 hasRelatedWork W2884628875 @default.
• W2017322529 hasRelatedWork W2901219523 @default.
• W2017322529 hasRelatedWork W4234705648 @default.
• W2017322529 hasVolume "13" @default.
• W2017322529 isParatext "false" @default.
• W2017322529 isRetracted "false" @default.
• W2017322529 magId "2017322529" @default.
• W2017322529 workType "article" @default.